U.S. Markets open in 13 mins

Cytek Biosciences, Inc. (CTKB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.28+0.25 (+1.04%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.03
Bid23.30 x 3200
Ask27.00 x 1200
Day's Range23.33 - 24.36
52 Week Range17.40 - 28.70
Avg. Volume359,487
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.33
  • GlobeNewswire

    Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay

    Optimized for Cytek Aurora Cell Analysis Systems; Delivers Turnkey Solution for Immunophenotyping Cytek Biosciences Cytek’s new immunoprofiling assay includes reagents and tools to simplify the workflow from sample preparation to data analysis, allowing researchers to obtain relevant data quickly and shorten the time from biological question to answer. FREMONT, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- The field of medical research has a new tool to develop vaccines, personal immunotherapies, an

  • GlobeNewswire

    Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

    FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference. Cytek’s management is scheduled to present on Tuesday, September 14th, at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors

  • GlobeNewswire

    Cytek Biosciences Reports Second Quarter 2021 Financial Results

    FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Revenue was $30.4 million for the second quarter, representing a 59% increase over the second quarter of 2020Expanded the installed base to 855 instruments, with 104 instrument placements during the second quarterLaunched the Cytek Aurora Cell Sorter (CS), a high-dimensional benc